Enanta Pharmaceuticals, Inc.

Kaicheng Zhu

Yat Sun Or

Jianming Yu

In Jong Kim

Kevin McGrath

Adam Szymaniak

Tyler Mann

Long Nguyen

Solymar Negretti-Emmanuelli

Guoqiang Wang

Ruichao Shen

Hui Cao

Jiajun Zhang

Tao Wang

George G Wu

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Antiviral heterocyclic compounds

The present invention relates to processes for preparing a Compound (1): or a pharmaceutically acceptable salt or solvate thereof. Compound (1) is useful as in many pharmaceutical agents, especially is useful as key intermediate in the synthesis of certain SARS-CoV-2 3CLpro inhibitors.

Processes for the preparation of 4,6,7-trifluoro-1H-indole-2-carboxylic acid

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Benzodiazepine derivatives as RSV inhibitors

Growing community of inventors

Belmont, MA, United States of America

Kaicheng Zhu